Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Biological Causes of Schizophrenia01:29

Biological Causes of Schizophrenia

103
Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
103
Complement System01:27

Complement System

2.5K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
2.5K
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

756
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
756
Positive Symptoms Schizophrenia: Hallucinations and Delusions01:26

Positive Symptoms Schizophrenia: Hallucinations and Delusions

107
Schizophrenia is a complex psychiatric disorder characterized by a range of symptoms that significantly impact cognition, behavior, and emotional regulation. Among these, the positive symptoms stand out as they involve the addition or exaggeration of normal mental functions, deviating markedly from typical behavior and perception. Hallucinations and delusions are prominent positive symptoms, each profoundly affecting the individual's experience of reality.
Hallucinations
Hallucinations in...
107
Psychological and Sociocultural Causes of Schizophrenia01:29

Psychological and Sociocultural Causes of Schizophrenia

145
Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
145
Negative and Cognitive Symptoms of Schizophrenia01:30

Negative and Cognitive Symptoms of Schizophrenia

96
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
96

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between changes in sleep quality and serum pro-inflammatory cytokine levels in patients with major depressive disorder following duloxetine treatment.

Annals of general psychiatry·2026
Same author

Effect of age, sex, and BMI on serum olanzapine levels and their correlation with metabolic parameters and serum pro-inflammatory cytokine levels in schizophrenia patients.

BMC psychiatry·2026
Same author

Alterations in serum melatonin, IL-6 and BDNF levels and their clinical correlations in first-episode major depressive disorder.

Annals of general psychiatry·2026
Same author

Prefrontal cortex-extracellular vesicle RNAs coupling in alcohol use disorder: towards non-invasive biomarkers and targeted therapeutics.

Artificial cells, nanomedicine, and biotechnology·2026
Same author

Bone marrow mesenchymal stem cell exosome-derived miR-223 regulated cellular pyroptosis of macrophage in osteomyelitis through regulating LACC1.

Scientific reports·2025
Same author

Associations of ANKK1 (rs1800497) polymorphism with glucose and lipid metabolism in patients with schizophrenia treated with olanzapine: a retrospective study.

Annals of general psychiatry·2025

Related Experiment Video

Updated: Jul 25, 2025

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

11.9K

Peripheral Complement Factor-Based Biomarkers for Patients with First-Episode Schizophrenia.

Yin Cao1,2,3,4, Yayun Xu5,6,7, Qingrong Xia1,2,3,4

  • 1Affiliated Psychological Hospital of Anhui Medical University, Hefei, People's Republic of China.

Neuropsychiatric Disease and Treatment
|June 29, 2023
PubMed
Summary

Serum complement factors like C1, C2, C3, C4, and CH50 show potential as biomarkers for diagnosing schizophrenia (SCZ). Elevated levels in SCZ patients suggest their utility in early detection and understanding the disease.

Keywords:
biomarkercomplement factorsdiagnosisschizophreniaserum

More Related Videos

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

7.9K
Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry
07:20

Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry

Published on: May 19, 2020

7.3K

Related Experiment Videos

Last Updated: Jul 25, 2025

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

11.9K
A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

7.9K
Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry
07:20

Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry

Published on: May 19, 2020

7.3K

Area of Science:

  • Neuroscience
  • Immunology
  • Biomarker Discovery

Background:

  • Schizophrenia (SCZ) is a severe neurological disorder impacting millions globally.
  • Identifying reliable biomarkers is crucial for early diagnosis, understanding pathogenesis, and prognosis.
  • The complement system, a key part of immunity, is increasingly explored for its role in neurological disorders.

Purpose of the Study:

  • To investigate serum complement factors as potential diagnostic biomarkers for first-episode schizophrenia (SCZ).
  • To differentiate SCZ patients from healthy controls using complement factor levels.
  • To explore correlations between complement factor concentrations and SCZ symptom severity.

Main Methods:

  • Study included 89 first-episode SCZ patients and 89 healthy controls.
  • Serum levels of five complement factors (C1, C2, C3, C4, CH50) were measured using ELISA.
  • Receiver Operating Characteristic (ROC) curve analysis assessed diagnostic value; Pearson's correlation examined relationships with symptom scales (BPRS, SANS, SAPS).

Main Results:

  • Significantly increased serum levels of C1, C2, C3, C4, and CH50 were observed in SCZ patients compared to controls.
  • A combined panel of these complement factors achieved an AUC of 0.857 in discriminating SCZ patients.
  • Serum levels of C2, C3, and CH50 positively correlated with SANS, SAPS, and BPRS scores, respectively.

Conclusions:

  • Circulating complement factors (C1, C2, C3, C4, CH50) show promise as diagnostic biomarkers for first-episode schizophrenia.
  • These findings support the role of the complement system in SCZ pathophysiology.
  • Further research can validate these factors for clinical diagnostic tools.